Generic Name and Formulations:
Sulindac 200mg; scored tabs.
Various generic manufacturers
Indications for Sulindac:
Rheumatoid arthritis. Osteoarthritis. Ankylosing spondylitis. Acute painful shoulder. Acute gouty arthritis.
Take with food. 150mg twice daily; max 400mg/day. Acute painful shoulder or gouty arthritis: 200mg twice daily, usually for 7–14 days.
Aspirin allergy. Coronary artery bypass graft surgery.
Advanced renal disease: not recommended. Active or history of GI bleeding, peptic ulcer, or kidney stones. Heart failure. Impaired renal or hepatic function. Edema. Hypertension. Bleeding disorders. Sepsis. Diabetes. Preexisting asthma. Maintain adequate hydration. Monitor blood, hepatic, renal, and ocular function in chronic use. Discontinue if unexplained fever, pancreatitis, or liver dysfunction occurs. Systemic lupus erythematosus and mixed connective tissue disease. Elderly. Debilitated. Pregnancy (Cat.C); avoid in late pregnancy. Nursing mothers: not recommended.
Increased risk of GI toxicity with aspirin, other NSAIDs, alcohol, smoking. Probenecid increases serum levels. Diflunisal reduces serum levels. Antagonized by, and peripheral neuropathy with, DMSO. Monitor anticoagulants, antihyperglycemics. Caution with methotrexate, cyclosporine, nephrotoxic drugs (increased toxicity). Increased serum lithium levels (monitor). May antagonize diuretics, ACE inhibitors, angiotensin II antagonists (monitor).
NSAID (indene deriv.).
GI ulcer/bleeding/pain, dyspepsia, nausea, diarrhea, constipation, rash (discontinue if occurs), dizziness, headache, tinnitus, edema, nephritis, nephrotic syndrome, pancreatitis, jaundice, hepatitis. See literature re: risk of cardiovascular events.
Formerly known under the brand name Clinoril.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|